What is claimed is:

1. Use of a composition comprising nanoparticles comprising paclitaxel and an albumin in the manufacture of a medicament for treating NSCLC in an individual, wherein the medicament is to be administered with an effective amount of a platinum-based agent, wherein the treatment is to be based upon the NSCLC being squamous cellular carcinoma.

2. The use of claim 1, wherein the individual for treatment is to be selected based on the individual having squamous cellular carcinoma.

3. The use of claim 1 or 2, wherein the treatment is further based on the NSCLC having a high level of caveolin-1 (CAV-1).

4. The use of any one of claims 1-3, wherein the effective amount of the composition comprising nanoparticles comprising paclitaxel and albumin is between about 50 mg/m^2 and about 125 mg/m^2.

5. The use of any one of claims 1-4, wherein the composition comprising nanoparticles comprising paclitaxel and albumin is to be administered weekly.

6. The use of any one of claims 1-5, wherein the effective amount of the platinum-based agent is between about AUC=2 and about AUC=6.

7. The use of any one of claims 1-6, wherein the platinum-based agent is to be administered once every three weeks.

8. The use of any one of claims 1-7, wherein the effective amount of the composition comprising nanoparticles comprising paclitaxel and albumin is 100 mg/m^2, to be administered weekly and the effective amount of the platinum-based agent is AUC=6, to be administered once every three weeks.

9. The use of any one of claims 1-8, wherein the composition comprising nanoparticles comprising paclitaxel and albumin and the platinum-based agent are to be administered parenterally.

10. The use of any one of claims 1-8, wherein the composition comprising nanoparticles comprising paclitaxel and albumin and the platinum-based agent are to be administered intravenously.

11. The use of any one of claims 1-10, wherein the platinum-based agent is carboplatin.

12. The use of any one of claims 1-11, wherein the medicament is to be administered with thoracic radiation.

13. A method of assessing whether an individual with NSCLC will respond to treatment comprising assessing *in vitro*, from a sample derived from the individual, for squamous cellular carcinoma, wherein squamous NSCLC indicates the individual will be responsive to the treatment and the treatment comprises i) an effective amount of a composition comprising nanoparticles comprising paclitaxel and an albumin and ii) an effective amount of a platinum-based agent.

14. A method of identifying an individual with NSCLC likely to respond to treatment comprising a) a composition comprising nanoparticles comprising paclitaxel and an albumin and b) a platinum-based agent comprising: (A) assessing *in vitro*, from a sample derived from the individual, for squamous cellular carcinoma; and (B) identifying the individual having squamous cellular carcinoma.

15. The use of claim 1, wherein an effective amount of the composition comprising nanoparticles comprising paclitaxel and albumin is 100 mg/m^2 to be administered weekly and an effective amount of the platinum-based agent is AUC=6.

16. The use of claim 1 or claim 15, wherein the composition comprising nanoparticles comprising paclitaxel and albumin is to be administered weekly and the platinum-based agent is to be administered once every three weeks.

17. The use of any one of claims 1, 15, and 16, wherein the composition comprising nanoparticles comprising paclitaxel and albumin and the platinum-based agent are to be administered intravenously.

18. The use of any one of claims 1 and 15-17, wherein the NSCLC is advanced NSCLC.

19. The use of any one of claims 1 and 15-18, wherein the treatment is to be used as first-line therapy.

20. The use of any one of claims 1 and 15-19, wherein the platinum based agent is carboplatin.

21. The use of any one of claims 1-12 and 15-20, wherein paclitaxel in the nanoparticles is coated with albumin.

22. The use of any one of claims 1-12 and 15-21, wherein the albumin is human albumin.

23. The use of any one of claims 1-12 and 15-21, wherein the albumin is human serum albumin.

24. The use of any one of claims 1-12 and 15-23, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.

25. The use of any one of claims 1-12 and 15-24, wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 9:1 or less.

26. The use of claim 25, wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 9:1.

27. The use of any one of claims 1-12 and 15-26, wherein the NSCLC is Stage IIIB NSCLC or Stage IV NSCLC.

28. The use of any one of claims 1-12 and 15-27, wherein the individual is human.

29. The method of claim 13 or 14, wherein paclitaxel in the nanoparticles is coated with albumin.

30. The method of any one of claims 13-14 and 29, wherein the albumin is human albumin.

31. The method of any one of claims 13-14 and 29, wherein the albumin is human serum albumin.

32. The method of any one of claims 13-14 and 29-31, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.

33. The method of any one of claims 13-14 and 29-32, wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 9:1 or less.

34. The method of claim 33, wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 9:1.

35. The method of any one of claims 13-14 and 29-34, wherein the NSCLC is Stage IIIB NSCLC or Stage IV NSCLC.

36. The method of any one of claims 13-14 and 29-35, wherein the individual is human.